James Hardie Lifts FY27 Cash Flow Target 20% to $600M, Shares Dip 5%
JHX sits 64% above its 52-week low of $16.46.
Summary
James Hardie raised its FY27 free cash flow guidance by 20% to about $600M at its first investor day since the AZEK merger, and said it will hit its $125M cost synergy target a year early. Sales and adjusted EBITDA guidance were reaffirmed, but the market focused on the unchanged earnings outlook and the absence of a housing recovery assumption. Shares fell 5% as the cash flow upgrade was partly attributed to the absence of $207M in deal and integration costs that depressed FY26. The company also introduced a 4-7% organic growth target and called the $500M revenue synergy target a floor. The €840M sale of Fermacell to Holcim is expected to close in H1 FY27, funding debt paydown and a $250M buyback.
At the time of this announcement, JHX was trading at $27.01 on NYSE in the Manufacturing sector, with a market capitalization of approximately $15.7B. The 52-week trading range was $16.46 to $31.43. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Market Index.